Skip to Main Content

Paper Details

A Phase 1 Trial of Durvalumab in Combination with Bacillus Calmette-Guerin (BCG) or External Beam Radiation Therapy in Patients with BCG-unresponsive Non-muscle-Invasive Bladder Cancer: The Hoosier Cancer Research Network GU16-243 ADAPT-BLADDER Study.
Eur Urol
10
2023
Cancer, Durvalumab, Invasive Bladder Cancer, NMIBC, PD-L1, Patients, autoimmune hepatitis, non-muscle-invasive bladder cancer, patient, patients
Author NameAffiliation
Phuoc T TranJohns Hopkins University Sidney Kimmel Comprehensive Cancer Center, USA The Johns Hopkins Greenberg Bladder Cancer Institute, USA The James Buchanan Brady Urological Institute, Johns Hopkins School of Medicine, University of Maryland School of Medicine
Danny Y SongJohns Hopkins University Sidney Kimmel Comprehensive Cancer Center, USA The Johns Hopkins Greenberg Bladder Cancer Institute, USA The James Buchanan Brady Urological Institute, Johns Hopkins School of Medicine
Luigi MarchionniJohns Hopkins University Sidney Kimmel Comprehensive Cancer Center, USA The Johns Hopkins Greenberg Bladder Cancer Institute, USA Johns Hopkins University School of Medicine, Center for Computational Genomics, Weill Cornell Medical College
Luigi MarchionniJohns Hopkins University Sidney Kimmel Comprehensive Cancer Center, USA The Johns Hopkins Greenberg Bladder Cancer Institute, USA Johns Hopkins University School of Medicine, Center for Computational Genomics, Weill Cornell Medical College
David J McConkeyJohns Hopkins University Sidney Kimmel Comprehensive Cancer Center, USA The Johns Hopkins Greenberg Bladder Cancer Institute, USA The James Buchanan Brady Urological Institute
Eric M HorwitzFox Chase Cancer Center
  • 1 - 6

Datasets

Release 1.2